Compare Quest Diagnostics Inc (DGX) vs Goodyear Tire & Rubber Co (GT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Goodyear Tire & Rubber Co — how do they compare? Quest Diagnostics Inc trades at $230.86 (market cap $25.48B), while Goodyear Tire & Rubber Co trades at $4.68 (market cap $1.37B). The key difference: Quest Diagnostics Inc is far larger — about 18.6× Goodyear Tire & Rubber Co's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Goodyear Tire & Rubber Co pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Goodyear Tire & Rubber Co for 57 Days on average.
| DGX | GT | |
|---|---|---|
Market Cap | $25.48B | $1.37B |
Volume | 941,866 | 9,470,773 |
Sector | Health | Consumer Cyclical |
52-Week High | $247.45 | $10.54 |
52-Week Low | $173.49 | $4.66 |
Typical Hold Time | 56 Days | 57 Days |
Enterprise Value | $31.23B | $8.72B |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $227.00, down 0.64% with a bearish technical signal. The company shows strong fundamentals with three consecutive quarterly earnings beats and revenue growth from $9.9B in 2024 to $11.0B in 2025. Recent developments include positive clinical study results and a new Apple Health integration, though Medicare reimbursement cuts pose headwinds. The stock trades near support at $226 with oversold RSI readings suggesting potential for near-term bounce.
DGX presents a mixed outlook with solid execution offset by regulatory risks. The 10% upside to consensus price target of $250 offers opportunity, but Medicare payment reductions and rising debt levels require monitoring. Recent earnings momentum and strategic partnerships support growth, making DGX suitable for investors comfortable with healthcare sector volatility.
Goodyear (GT) trades at $4.68, down 0.21% on the day, with a bearish technical signal and weak profitability metrics including a negative net income margin and ROE. Recent earnings show mixed results, with a Q2 2026 loss of $0.61 per share beating expectations but revenue declining. The company's restructuring efforts focus on premium tire segments and cost management, while cash flow trends show modest improvement with a net cash flow of $46 million in 2025.
The outlook remains challenging due to persistent losses and high debt, but analyst consensus suggests upside with a $8.00 price target. Key risks include volume pressure, competitive threats, and execution of the turnaround plan. Investment opportunity hinges on successful margin expansion and debt reduction, though near-term volatility is likely amid macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Goodyear Tire & Rubber Co
Goodyear Tire & Rubber Co manufactures and sells a variety of rubber tires under the Goodyear brand name. The firm's tires are used for automobiles, trucks, buses, aircraft, motorcycles, mining equipment, farm equipment, and industrial equipment.
Read more on GT →
